ADPT | Adaptive Biotechnologies Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.20 - 6.41
52 Week Range	2.2800 - 7.07
Beta	2.28
Implied Volatility	909.73%
IV Rank	26.76%
Day's Volume	409,931
Average Volume	1,261,806
Shares Outstanding	147,579,000
Market Cap	943,029,810
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-06-27

Valuation
Profitability
Growth
Health
P/E Ratio	-4.77
Forward P/E Ratio	-4.89
EPS	-1.34
1YR Price Target	15.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	709
Country	USA
Website	ADPT

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

ADPT's peers: VERV, BEAM, CRBU, SANA, VECT, KNTE, RPRX, IKNA, CWBR, HEPA, RAIN, KRYS, AVRO, ENVB, ELEV, ZURA, RPHM, LEGN, VIR, APLS

*Chart delayed

Analyzing fundamentals for ADPT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is frighteningly weak. For more detailed analysis please see ADPT Fundamentals page.

Watching at ADPT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ADPT Technicals page.